FCMI
KPTI icon

Foresite Capital Management I’s Karyopharm Therapeutics KPTI Stock Holding History

Foresite Capital Management I’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-66,618
Closed -$37.4M – 5
2014
Q4 		$37.4M Sell
66,618
-5,190
-7% -$2.95M 55.08% 1
2014
Q3 		$37.6M Sell
71,808
-20,019
-22% -$11.3M 36.04% 1
2014
Q2 		$64.1M Sell
91,827
-13,889
-13% -$6.46M 53.75% 1
2014
Q1 		$49M Hold
105,716
– – 34.41% 1
2013
Q4 		$32.6M Buy
+105,716
New +$29.2M 31.69% 1

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Foresite Capital Management I's KPTI Position: Q1 2015 in Review

Foresite Capital Management I sold out of Karyopharm Therapeutics (KPTI) in Q1 2015, closing a stake of 66,618 shares — an estimated $37.4M sold.

Foresite Capital Management I first reported a position in KPTI in Q4 2013 and held it in 5 quarters. The position peaked at $64.1M in Q2 2014. 85 funds tracked by Wall St. Rank hold KPTI as of Q1 2015.

  • Foresite Capital Management I reported no remaining Karyopharm Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Foresite Capital Management I sold 66,618 Karyopharm Therapeutics shares in Q1 2015, an estimated $37.4M.
  • Foresite Capital Management I first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 5 quarters.
  • Foresite Capital Management I's Karyopharm Therapeutics position peaked at $64.1M in Q2 2014.
  • 85 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2015.

Based on Foresite Capital Management I's 13F filing for Q1 2015, filed 5 May 2015.